Section Arrow
CLYM.NASDAQ
- Climb Bio Inc
Quotes are at least 15-min delayed:2026/07/16 20:29 EDT
Regular Hours
Last
 12.58
-1.29 (-9.30%)
Day High 
13.84 
Prev. Close
13.87 
1-M High
14.415 
Volume 
1.51M 
Bid
12
Ask
12.5
Day Low
12.01 
Open
13.57 
1-M Low
10.71 
Market Cap 
794.24M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.46 
20-SMA 12.87 
50-SMA 11.78 
52-W High 14.415 
52-W Low 1.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.77/-0.98
Enterprise Value
794.52M
Balance Sheet
Book Value Per Share
2.59
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.